Romosozumab (Evenity) Builds Bone and Blocks Resorption Simultaneously in Postmenopausal Women — A Paradigm Shift Beyond Bisphosphonates

The treatment of postmenopausal osteoporosis is moving into a new paradigm. Amgen and UCB’s romosozumab (brand name Evenity) is a first-in-class monoclonal antibody that operates through a different mechanism than bisphosphonates. It blocks sclerostin to stimulate osteoblast formation while also partially suppressing bone resorption — anabolic and antiresorptive activity in one molecule.

Existing bisphosphonates (alendronate, risedronate, zoledronate) are all antiresorptive only. They don’t build new bone — they only slow the rate at which existing bone is lost. Denosumab also falls in the antiresorptive category. Bone-building drugs were limited to teriparatide (Forteo, PTH 1-34) and abaloparatide (Tymlos, PTHrP), but these had weak resorption-inhibition. Romosozumab is the first drug to activate both circuits simultaneously.

ARCH was the pivotal trial. 4,093 postmenopausal women with osteoporosis received romosozumab for 12 months → alendronate for 12 months, versus alendronate for 24 months. At 24 months, vertebral fracture risk dropped 48% (romosozumab arm advantage). Clinical fracture down 27%, non-vertebral fracture down 19%. The FRAME trial (n=7,180) showed 73% vertebral fracture reduction versus placebo at 12 months.

Sclerostin is a protein secreted by osteocytes that blocks the Wnt signaling pathway, suppressing new bone formation — effectively a “bone formation brake.” Romosozumab releases this brake, causing osteoblast activity to surge. It also partially attenuates RANKL signaling, reducing osteoclast activity.

Dosing protocol:

• Year 1: 210mg subcutaneous monthly (12 doses total)
• After Year 1: transition to antiresorptive (denosumab or alendronate) → maintain effect

The key is the 1-year limit. After 12 months, efficacy plateaus, and transitioning to antiresorptive cement the gains. Not a lifelong drug.

First-line indications:

• Postmenopausal women at very high fracture risk
• Patients with prior fracture history
• T-score < -2.5 with additional risk factors
• Patients with insufficient response or intolerance to bisphosphonates

Side effects are generally well tolerated. Mild injection site reactions, joint pain, and headache match placebo. But there’s a boxed warning: possible increased cardiovascular event risk (myocardial infarction, stroke). Patients with cardiovascular events within the past year are contraindicated. Cardiovascular signal in ARCH follow-up requires careful patient selection.

Cost: estimated US market price $20,000–25,000 for the 1-year course. In Korea, insurance coverage since 2024 has reduced the out-of-pocket burden. Specialty disease cost reimbursement for osteoporosis is worth checking.

The lifestyle matrix remains essential. Romosozumab alone doesn’t maximize efficacy. Recommended companions:

• Calcium 1,200mg/day: combined diet + supplementation
• Vitamin D 2,000~4,000 IU/day: maintain 25(OH)D ≥ 30 ng/mL
• Protein 1.0–1.2g/kg/day: substrate for bone synthesis
• Resistance training 2~3×/week: mechanical stimulus on osteocytes
• Balance exercise: fall prevention (yoga, tai chi)
• No smoking + alcohol restraint

In the period when bone density loss accelerates in postmenopausal women (50s~60s), serious fracture risk assessment makes romosozumab a meaningful first-line option. T-score, FRAX score, and fracture history are the decision indicators. For simple osteopenia (T-score -1.0 to -2.5), bisphosphonates or natural matrix approaches start the ladder.

Osteoporosis prevalence in postmenopausal Korean women is 30–50%, but diagnosis and treatment rates remain below one-third of that. New options like romosozumab can raise patient motivation at the diagnostic stage. Annual osteoporosis screening (DXA), 25(OH)D measurement, and the vitamin D + calcium + protein + exercise matrix are basic post-50 women’s healthcare.